1. Background {#sec0005}
=============

Prevention of pneumococcal disease is a major, international public health priority due to the high burden of disease and associated mortality, especially in children in developing countries [@bib0195]. Pneumococcal conjugate vaccines (PCVs) prevent pneumococcal disease by reducing the carriage of serotypes included in the vaccine [@bib0200], [@bib0205]. PCVs are currently used in routine childhood vaccination programmes in many developed and developing countries. Because children are the main drivers of transmission [@bib0210], vaccinating children also protects older members of the community from both nasopharyngeal carriage and invasive disease [@bib0200], [@bib0215], [@bib0220], [@bib0225], [@bib0230], [@bib0235]. Some studies undertaken after the introduction of PCVs have shown an increase in both the incidence of invasive pneumococcal disease and in the prevalence of carriage caused by pneumococcal serotypes not included in the vaccine (non-vaccine-serotypes or NVT), [@bib0200], [@bib0205], [@bib0230], [@bib0240], [@bib0245], [@bib0250], [@bib0255]. This replacement of VT serotypes with NVT serotypes has also been observed in non-vaccinated older members of vaccinated communities [@bib0260]. However, the capsule is a determinant of virulence, and VT serotypes tend to be more virulent than NVT [@bib0265]. Consequently, there has been an overall reduction in invasive pneumococcal disease since the introduction of pneumococcal vaccination, despite serotype replacement [@bib0230].

Because conjugate vaccines target the pneumococcal capsule, pneumococci can evade vaccine-induced immunity by changing their serotype, or losing their capsule altogether, through genetic recombination, described as switching [@bib0270], [@bib0275].

The first licensed PCV vaccine included 7 out of the more than 90 pneumococcal serotypes. This vaccine did not include the most prevalent serotypes causing disease in Africa and other developing regions. To address this challenge, PCV13 was licensed based on safety and immunogenicity data in comparison with PCV7. PCV13 contains 13 capsular pneumococcal polysaccharides that are individually conjugated to non-toxic diphtheria protein. In addition to the 7 serotypes in PCV7 (4, 6B, 9V, 14,18C, 19F and 23F), PCV13 contains serotypes 1, 3, 5, 6A, 7F and 19A. Together these are the 13 most common serotypes causing invasive pneumococcal disease globally [@bib0280]. The impact of PCVs on nasopharyngeal carriage is considered a predictor of vaccine effectiveness [@bib0285] and carriage studies can be used to predict the potential impact of different formulations of PCVs on VT among the vaccinated population (direct effect) and other age groups (indirect effect). A vaccine trial conducted in Israel, which compared the efficacy of PCV13 versus PCV7, showed a reduction in the acquisition and prevalence of nasopharyngeal colonization for the additional serotypes included in PCV13 as well as a lower prevalence of serotypes 6C and 19F [@bib0290]. The objective of this study was to compare the effectiveness of three doses of PCV13 with that of three doses of PCV7 in preventing pneumococcal nasopharyngeal colonization among infants in The Gambia and to assess the indirect effect of this formulation on their mothers. In addition, we analyzed the molecular basis for the observed increase in the prevalence of non-typable pneumococcus after PCV13 vaccination.

2. Materials and methods {#sec0010}
========================

2.1. Pneumococcal conjugate vaccination in The Gambia {#sec0015}
-----------------------------------------------------

The Gambia was the second country in Africa to introduce PCV7 as part of its Expanded Programme of Immunization (EPI), starting in the second half of 2009 and following three-dose schedule with vaccine given at the age of 2, 3 and 4 months of age. Although there was no formal catch-up campaign, most of children under 2 years of age received one dose of PCV7 soon after its introduction. In June 2011, PCV7 was replaced by PCV13 in the EPI programme. EPI coverage in the country is \>90% for DPT3 and a similar coverage is expected for PCVs [@bib0295].

2.2. Study population {#sec0020}
---------------------

The study was conducted in a peri-urban area situated on the western margin of The Gambia, approximately 20 km from the capital Banjul. The population of the study area is ethnically mixed, and engaged in a wide range of occupations, including working for government services, some professions and trading. The climate of the area is typical of the sub-Sahel with a long dry season from November to May.

The study was carried out at two health centres, Sukuta Health Centre and Jammeh Foundation for Peace. These are government run health centres and vaccination clinics located approximately 8 km from Fajara where the main laboratories at the Medical Research Council (MRC) are based. Children and their mothers were identified and recruited in the vaccination clinics of the health centres. These health centres serve a local community of more than 25,000 inhabitants each, with an overall annual birth cohort of more than 7000 children.

2.3. Study design and samples {#sec0025}
-----------------------------

We conducted a study of pneumococcal nasopharyngeal carriage before and after the introduction of PCV13. The first cross-section survey (CSS1) was conducted between March and June 2011 among children who had received three doses of PCV7. The second survey (CSS2) was conducted following the introduction of PCV13 between March and June 2012 among children who had received three doses of PCV13.

Infants 6--11 months of age were recruited at EPI vaccine clinics. To be eligible for the study, children had to be healthy, to have received three documented doses of PCV (PCV7 in CSS1 or PCV13 in CSS2) with the third dose received at least 4 weeks before entering the survey. If consent was given, a nasopharyngeal swab (NPS) was taken from the infant and their mother. Demographic data and data on risk factors for carriage were obtained by interviewing the mother using a structured questionnaire.

The study was approved by the joint MRC/Gambia Government Ethics Committee and by the ethics committee of the London School of Hygiene and Tropical Medicine.

2.4. NPS collection {#sec0030}
-------------------

NPSs were collected from the posterior wall of the nasopharynx using an alginate swab and immediately inoculated into vials containing skim milk--tryptone--glucose--glycerol (STGG) transport medium, which was placed in a cold box before transfer to the Medical Research Council Laboratories at Fajara within 8 h of collection, in accordance with the WHO protocol for evaluation of pneumococcal carriage [@bib0300]. Inoculated vials were stored at −70 °C until tested in batches.

### 2.4.1. Microbiological methods {#sec0035}

Frozen STGG containing nasopharyngeal swabs were initially thawed on ice and then vortexed briefly for a minimum of 20 s. 200 μl of STGG was transferred into 5 ml of Todd Hewitt broth containing 5% yeast extract, and 1 ml of rabbit serum. The mixture was vortexed briefly before incubating for 4--6 h at 37 °C. At the end of the incubation period, the broth was vortexed again and 50 μl aliquot inoculated on to gentamycin blood agar (GBA). The inoculum was streaked onto four quadrants in order to semi quantitatively determine the bacterial load (from 1 to 4) as described elsewhere [@bib0305]. After 20--24 h incubation at 37 °C with 5% CO~2~, GBA plates were examined for alpha hemolytic colonies. Presumptive pneumococcal colonies were then screened for optochin susceptibility.

Pneumococcal isolates were serotyped using the latex agglutination techniques as described previously [@bib0310]. All non-typable isolates were repeated and only considered non-typables when confirmed by the second test.

2.5. Sample size calculation {#sec0040}
----------------------------

We chose a sample size of 350 infants per CSS to detect a 40% reduction in the prevalence of PCV(13-7)-VT (from 24% to 14%), with 90% power and a type 1 error of 5%.

2.6. Statistical analysis {#sec0045}
-------------------------

The overall prevalence of pneumococcal carriage, the prevalence of individual serotypes, and the prevalence of VT serotypes was determined in each survey. The latter were classified in three ways: (i) serotypes included in PCV7 (PCV7 VT), (ii) serotypes included in PCV13 (PCV13 VT), and (iii) serotypes included in PCV13 but not in PCV7 (PCV13-7 VT).

Poisson regression was used to estimate prevalence ratios comparing CSS1 and CSS2. For mothers and children the ratios were adjusted for maternal age, household size, health centre and maternal education. For children the ratios were additionally adjusted for age and gender, antibiotic use (of the infant) and exposure to smoke from cooking. *p*-Values and confidence intervals were calculated using robust variance estimates.

We used Fisher\'s exact to test the hypothesis that the proportion of PCV13 VT among non-typables that had lost their capsule was equal to the proportion in the population as a whole.

All analyses were done using Stata version 13.

Whole genome sequence analysis {#sec0050}
------------------------------

Whole genome sequencing (WGS) was conducted among non-typable pneumococci isolated from mothers and infants in both study CSSs.

Samples of genomic DNA from study pneumococcal isolates were sequenced using Illumina HiSeq, 100 bp paired end with 350 bp inserts. Kraken was used to differentiate between pneumococci and closely related species and to identify any potential contamination [@bib0315]. MLST was derived from *de novo* Velvet assemblies [@bib0320]. Detection of known serotype specific sequences in assemblies and mapping against known capsular loci was performed as previously described [@bib0325], [@bib0330].

Sequence reads were mapped against the reference genome for *S. pneumoniae* ATCC 700669 [@bib0335] using a pipeline developed in-house at The Sanger Institute that utilizes SMALT (<http://www.sanger.ac.uk/resources/software/smalt/>). In addition to the 34 non-typable genomes sequenced for this study a total of 64 isolates from independent pneumococcal sequencing projects were included in the analysis to give serological context to the phylogeny; six classically non-typable isolates [@bib0340], 52 Gambian isolates from a previous study [@bib0345] and a further 6 Gambian isolates from the Global Pneumococcal Sequencing project (<http://www.pneumogen.net/gps/>). The resultant alignment was reduced to variable sites and phylogeny created using RaxML [@bib0350]. Single nucleotide polymorphisms (SNPs) were reconstructed on the phylogeny using an in-house accelerated transformation parsimony method rooted on *Streptococcus pseudopneumoniae*. The phylogeny was visualized and annotated in ITOL [@bib0350]. The data were deposited in the ENA with accession numbers provided in the supplementary data.

3. Results {#sec0055}
==========

3.1. Study profile {#sec0060}
------------------

Six hundred and eighty-nine infants and their mothers were recruited and sampled from the study (339 in CSS1 and 350 in CSS2). Approximately half of the recruited infants were male (50.2%) and their median age was 8 months. Because 11 children were twins, only 678 mothers were sampled \[median age 25 years\]. Sampling occurred between 24th March and 9th June in 2011 for CSS1; and 27th March and 7th of June 2012 for CSS2. [Table 1](#tbl0005){ref-type="table"} provides a summary of the epidemiological characteristics of individuals included in each CSS survey.

3.2. Prevalence of pneumococcal carriage pre and post PCV13 introduction {#sec0065}
------------------------------------------------------------------------

*Infants*: The overall prevalence of pneumococcal carriage among infants was similar in both surveys (85.8% and 84.3%, *p* = 0.594). However, the prevalence of VT decreased between CSS1 and CSS2 \[from 23.9% to 13.7% (*p* \< 0.001) for PCV(13-7)VT; from 33.3% to 18.3% (*p* \< 0.001) for PCV13-VT; and from 9.4 to 4.9 (*p* = 0.025) for PCV7-VT\]. The decrease in VT prevalence was mainly due to a decreasing in serotype 6A (from 15.3% to 5.7% -- *p* \< 0.001) and 19F (from 5.6% to 1.7% -- *p* = 0.007). The prevalence of non-typable serotypes increased in CSS2 (from 0.3% to 6.0% -- *p* \< 0.001) ([Table 2](#tbl0010){ref-type="table"}). Similar results were found in the crude and adjusted analyses ([Table 2](#tbl0010){ref-type="table"}). Apart from the non-typables, there was no significant increase of any NVT.

*Mothers*: The overall prevalence of pneumococcal carriage among mothers was lower than in infants but similar in CSS1 and CSS2 (23.0% versus 24.2%, *p* = 0.718). For the different study endpoints, differences between study CSSs were small and did not reach statistical significance in the crude or adjusted analysis ([Table 3](#tbl0015){ref-type="table"}). The most prevalent serotypes among mothers were serotype 16 in CSS1 and 19A in CSS2.

3.3. Genotypic analysis of non-typable isolates {#sec0070}
-----------------------------------------------

WGS was performed for all 28 phenotypically non-typable isolates; 22 from the infants (1 in CSS1 and 21 in CSS2) and 6 from the mothers (1 and 5 in CSS1 and CSS2 respectively). Three (10.7%) of these isolates were *S. pseudopneumoniae*, 3 were of the classical non-typable lineage (10.7%) and the others \[22 out of 28 (78.6%)\] were of the typically encapsulated pneumococcal lineage and had lost their ability to express capsule through one of three different mechanisms ([Fig. 1](#fig0005){ref-type="fig"}). Sixteen of these appear to have a standard *cps* locus but a capsule was not phenotypically detected, one isolate only had remnants of the *cps* locus whilst the remaining 5 had acquired a locus typically found in classically non-typable isolates. These latter isolates were closely related and cluster in the phylogeny predominantly within a serotype 14 lineage ([Fig. 1](#fig0005){ref-type="fig"} and [Table 4](#tbl0020){ref-type="table"}), accounting for 4 out of the 5 NT isolates from a serotype 14 background.

Among the 16 infants carrying non-typable isolates that were not classical, 7 (43.7%) were of VT lineage. This is almost double the proportion of VT carriers among infant carriers in CSS2 (23.4%) (*p* = 0.076).

4. Discussion {#sec0075}
=============

The Gambia was the second African country to introduce PCV7 into the EPI. For two years children received PCV7, but soon after PCV13 was licensed, the earlier vaccine was replaced by the higher valency formulation. To the best of our knowledge, the impact of replacing PCV7 with PCV13 within EPI programmes has not yet been reported in the African continent. Our study showed that overall prevalence of pneumococcal nasopharyngeal carriage among infants was comparable between PCV7 and PCV13 vaccinated children but that the distribution of serotypes differed between groups, with a significant decrease of the additional serotypes included in PCV13 \[PCV(13-7)-VT\]. We also observed an increase on non-typables isolates in CSS2, mainly of serotypes that had lost their capsule, most likely in response to vaccine pressure. No significant increase of NVT between CSS was observed.

In PCV13 vaccinated infants, the prevalence of PCV(13-7)-VT almost halved. Most of the difference was attributable to a decrease in the prevalence of serotype 6A, from 15.3% in CSS1 to 5.7% in CSS2. Even with this decrease, the prevalence of serotype 6A was still 6% in CSS2 and represented 42% of all PCV(13-7)-VT serotypes. These results, along with previous results in The Gambia, suggest that cross-protection between 6A and 6B was probably very low, if any [@bib0225]. The observed decrease of serotype 19A was not statistically significant; it was the most prevalent PCV(13-7)-VT in CSS2, and accounted for 47% of all PCV(13-7)-VT serotypes.

A notable difference between CSS1 and CSS2 was the increase in non-typable isolates in CSS2 (adjusted RR among infants 19.82). Prevalence of non-typable isolates in CSS2 (6% in infants) was higher than in CSS1 and also higher than in previous studies conducted in The Gambia [@bib0225], [@bib0355]. The WGS analysis of these non-typables pneumococci showed that most of them were not among the classical non-typable lineage, but instead, represented serotypable isolates that did not express a capsule. Capsule loss is not a rare event in the pneumococcus [@bib0360]. However, because the prevalence of VT lineages among isolates with loss of capsule expression was higher than the overall prevalence of VT isolates among carriers, this loss of capsule expression may be, at least partly, due to a response of the pneumococcal population to vaccine selection pressure. Although this analysis was not statistically significant the study was not powered for this endpoint. If our findings are true, we may expect an increase in carriage of non-typable pneumococcus. Further monitoring is warranted to determine whether non-typable serotypes carried in the nasopharynx are associated with increase in disease.

Our results differ slightly from similar studies recently conducted in other continents. In Israel, investigators observed a moderate decrease of overall carriage [@bib0365] contrasting with our results where no effect on overall pneumococcal carriage was observed in either vaccinated infants or their mothers. In the US, the prevalence of carriage remained stable after PCV13 introduction but a moderate increase of NVT, mainly due to serotype 35B, was observed [@bib0370]. In Italy, a greater reduction of serotype 19A was observed in children vaccinated with PCV13 [@bib0375].

As young children are the major reservoir of *S. pneumoniae*, the impact of the vaccine on carriage in this group plays a significant role in determining the impact of the vaccine on the community as a whole [@bib0225]. We included mothers in our analysis as, among adults, they are likely to benefit soonest from the indirect effect of the vaccine. However, one year after vaccine introduction we did not find a reduction in PCV13 serotypes among mothers whose children had been vaccinated with PCV13. This emphasises the fact that the indirect protective effect of PCVs may take several years to reach their maximum impact, and is consistent with the prediction of a recent mathematical model that population-wide serotype replacement in The Gambia will occur over a five year period [@bib0380].

Unfortunately, because of the study design, it is impossible to account for increasing herd effect after PCV7 introduction. Some of the differences among infants in CSS1 and CSS2, such as the decrease in PCV7-VT, could be related to the time since PCV introduction rather than the effect of the new vaccine. However, the decrease of PCV(13-7)VT (which includes only the serotypes from PCV13 that are not included in PCV7) in CSS2 cannot be explained by the longer time since the introduction of PCV7 and therefore the most likely explanation is the introduction of the new formulation. Our findings are in line with data from a RCT conducted in Israel comparing PCV7 versus PCV13 [@bib0290]. Secular trends, however, can occur in a before and after design.

Despite the challenges considered above, our data show that PCV13 resulted in lower carriage of PCV(13-7)VT with the strongest effect on an important serotype, 6A. These findings represent the first evidence of the impact of PCV13 in nasopharyngeal colonization in Africa, which may serve as a predictor of vaccine effectiveness through both direct and indirect effects. In addition, our results suggest that non-typable isolates will probably become more common in Africa with increasing deployment of PCV13.
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###### 

Characteristics of the children and their mothers who participated in cross sectional surveys undertaken before (CSS1) and after (CSS2) the introduction of PCV13 into the Gambian EPI programme.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                               CSS1[a](#tblfn0005){ref-type="table-fn"} (*n* = 339)\   CSS2[a](#tblfn0005){ref-type="table-fn"} (*n* = 350)\
                                                         *n* (%)                                                 *n* (%)
  ------------------------------------------------------ ------------------------------------------------------- -------------------------------------------------------
  *Health centre*                                                                                                

  Jammeh Foundation                                      229 (67.6)                                              251 (71.7)

  Sukuta                                                 110 (32.4)                                              99 (28.3)

  Total                                                  339                                                     350

  *Gender*                                                                                                       

  Female                                                 159 (46.9)                                              184 (52.7)

  Male                                                   180 (53.1)                                              165 (47.3)

  Total                                                  339                                                     349

  *Antibiotic use*[b](#tblfn0010){ref-type="table-fn"}                                                           

  No                                                     295 (88.6)                                              319 (92.2)

  Yes                                                    38 (11.4)                                               27 (7.8)

  Total                                                  333                                                     346

  *Mother\'s schooling*                                                                                          

  None or \<1 year                                       137 (41.8)                                              110 (31.6)

  1-3 years                                              46 (14.0)                                               36 (10.3)

  4-6 years                                              80 (24.4)                                               44 (12.6)

  \>6 years                                              65 (19.8)                                               158 (45.4)

  Total                                                  328                                                     348

  *Mother cooks with child on back*                                                                              

  No                                                     226 (66.9)                                              189 (54.3)

  Yes                                                    112 (33.1)                                              159 (45.7)

  *Child age (months)*                                                                                           

  Median (IQR)                                           8.2 (7.0,9.6)                                           7.6 (6.7,9.2)

  *Household size*                                                                                               

  Median (IQR)                                           5.0 (4.0,7.0)                                           3.0 (3.0,5.0)

  *Mother\'s age (years)*                                                                                        

  Median (IQR)                                           24.5 (21.0,29.0)                                        25.0 (21.0,28.0)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

There were 11 pairs of twins (i.e., 22 twins in total), 8 pairs in the PCV-7 survey and 3 pairs in the PCV-13 survey. The number of mothers was 331 and 347 in CSS1 and CSS2 respectively.

Within one month before entering the study.

###### 

Prevalence of pneumococcal carriage in infants in surveys conducted before (CSS1) and after (CSS2) Introduction of PCV13 ito the Gambian EPI programme.

                     Prevalence of carriage   RR     *p*-Value[a](#tblfn0015){ref-type="table-fn"}   RRadj[b](#tblfn0020){ref-type="table-fn"}   *p*-Value             
  ------------------ ------------------------ ------ ----------------------------------------------- ------------------------------------------- --------------------- ---------
  *Vaccine groups*                                                                                                                                                     
  PCV13-VT           33.3                     18.3   0.55 (0.42,0.72)                                \<0.001                                     0.52 (0.39,0.69)      \<0.001
  PCV7-VT            9.4                      4.9    0.51 (0.29,0.91)                                0.025                                       0.52 (0.28,0.97)      0.039
  PCV(13-7)-VT       23.9                     13.7   0.57 (0.41,0.79)                                0.001                                       0.53 (0.38,0.74)      \<0.001
  Pneumococcus       85.8                     84.3   0.98 (0.92,1.05)                                0.594                                       1.00 (0.93,1.07)      0.897
                                                                                                                                                                       
  *PCV13-VT*                                                                                                                                                           
  1                  0                        0      NA                                              NA                                          NA                    NA
  3                  0                        0.3    NA                                              1.000                                       NA                    NA
  4                  0.6                      0      NA                                              0.242                                       NA                    NA
  5                  0.3                      1.4    4.84 (0.57,41.30)                               0.217                                       4.59 (0.55,38.43)     0.160
  6A                 15.3                     5.7    0.37 (0.23,0.61)                                \<0.001                                     0.35 (0.21,0.59)      \<0.001
  6B                 0.9                      0      NA                                              0.119                                       NA                    NA
  7F                 0                        0      NA                                              NA                                          NA                    NA
  9V                 0                        0      NA                                              NA                                          NA                    NA
  14                 0.6                      0.9    1.45 (0.24,8.65)                                1.000                                       2.12 (0.36,12.35)     0.403
  18C                0.6                      0      NA                                              0.242                                       NA                    NA
  19A                8.3                      6.3    0.76 (0.44,1.30)                                0.379                                       0.66 (0.39,1.10)      0.112
  19F                5.6                      1.7    0.31 (0.12,0.76)                                0.007                                       0.29 (0.10,0.78)      0.015
  23F                1.5                      2.3    1.55 (0.51,4.69)                                0.578                                       1.51 (0.49,4.64)      0.468
                                                                                                                                                                       
  *NVT*                                                                                                                                                                
  10A                4.7                      4      0.85 (0.42,1.71)                                0.711                                       0.89 (0.41,1.93)      0.761
  13                 3.5                      3.4    0.97 (0.44,2.13)                                1.000                                       1.06 (0.45,2.52)      0.892
  15B                8.3                      9.1    1.11 (0.68,1.80)                                0.688                                       1.40 (0.82,2.38)      0.220
  16                 5.9                      6.6    1.11 (0.62,1.99)                                0.755                                       1.00 (0.51,1.99)      0.992
  19C                0.9                      0.3    0.32 (0.03,3.09)                                0.366                                       0.18 (0.03,1.06)      0.058
  21                 3.2                      4.9    1.50 (0.71,3.15)                                0.377                                       1.50 (0.71,3.15)      0.288
  34                 3.8                      2.3    0.60 (0.25,1.42)                                0.272                                       0.54 (0.22,1.36)      0.194
  35B                4.7                      4.9    1.03 (0.53,2.00)                                1.000                                       0.88 (0.44,1.74)      0.713
  NT                 0.3                      6.0    20.34 (2.75150.60)                              \<0.001                                     19.82 (2.64,148.78)   0.004

RR, risk ratios; VT, vaccine types; NVT, non-vaccine types 6; NA, not applicable.

*p*-Value from Fisher\'s exact test.

Adjusted for maternal age, household size, schooling, health centre, gender, exposure to smoke from cooking.

###### 

Prevalence of pneumococcal carriage in mothers before (CSS1) and after (CSS2) introduction of PCV13 into the Gambian EPI programme.

                     Prevalence of carriage   RR     *p*-Value[a](#tblfn0025){ref-type="table-fn"}   RRadj[b](#tblfn0030){ref-type="table-fn"}   *p*-Value           
  ------------------ ------------------------ ------ ----------------------------------------------- ------------------------------------------- ------------------- -------
  *Vaccine groups*                                                                                                                                                   
  PCV13              6.6                      8.4    1.26 (0.74,2.14)                                0.467                                       1.14 (0.65,2.01)    0.651
  PCV7               2.7                      2.6    0.95 (0.38,2.38)                                1.000                                       0.85 (0.31,2.30)    0.744
  PCV(13-7)VT        3.9                      6.1    1.54 (0.78,3.03)                                0.222                                       1.39 (0.67,2.86)    0.377
  Pneumococcus       23.0                     24.2   1.05 (0.80,1.38)                                0.718                                       1.19 (0.88,1.60)    0.264
                                                                                                                                                                     
  *PCV13-VT*                                                                                                                                                         
  1                  0.3                      0      NA                                              0.488                                       NA                  NA
  3                  0                        0.3    NA                                              1.000                                       NA                  NA
  4                  0.6                      0.6    0.95 (0.13,6.74)                                1.000                                       1.09 (0.09,13.70)   0.945
  5                  0                        0.9    NA                                              0.249                                       NA                  NA
  6A                 1.8                      2.0    1.11 (0.38,3.28)                                1.000                                       1.25 (0.42,3.72)    0.685
  6B                 0                        0      NA                                              NA                                          NA                  NA
  7F                 0                        0      NA                                              NA                                          NA                  NA
  9V                 0                        0      NA                                              NA                                          NA                  NA
  14                 0.6                      0.3    0.48 (0.04,5.24)                                0.616                                       0.36 (0.06,2.16)    0.266
  18C                0.3                      0.6    1.91 (0.17,20.98)                               1.000                                       1.72 (0.05,60.93)   0.266
  19A                1.8                      3.2    1.75 (0.65,4.68)                                0.328                                       1.36 (0.44,4.21)    0.589
  19F                0.6                      0.3    0.48 (0.04,5.24)                                0.616                                       0.24 (0.02,3.07)    0.274
  23F                0.6                      0.9    1.43 (0.24,8.52)                                1.000                                       1.23 (0.24,6.37)    0.805
                                                                                                                                                                     
  *NVT*                                                                                                                                                              
  10A                0.6                      0.3    0.48 (0.04,5.24)                                0.616                                       0.53 (0.05,5.12)    0.580
  13                 0.6                      1.7    2.86 (0.58,14.09)                               0.287                                       3.07 (0.60,15.62)   0.177
  15B                0.6                      1.7    2.86 (0.58,14.09)                               0.287                                       2.72 (0.71,19.50)   0.120
  16                 2.4                      0.6    0.24(0.05,1.12)                                 0.058                                       0.15 (0.03,0.72)    0.018
  19C                1.2                      0      NA                                              0.056                                       NA                  NA
  21                 0.9                      0.9    0.95 (0.19,4.70)                                1.000                                       0.52 (0.07,4.05)    0.535
  34                 1.2                      1.2    0.95 (0.24,3.79)                                1.000                                       0.75 (0.11,4.93)    0.761
  35B                1.8                      0.6    0.32 (0.06,1.57)                                0.168                                       0.39 (0.08,1.87)    0.240
  NT                 0.3                      1.4    4.77 (0.56,40.67)                               0.217                                       3.93 (0.42,37.03)   0.231

RR, risk ratios; VT, vaccine types; NVT, non-vaccine types 6; NA, not applicable.

*p*-Value from Fisher\'s exact test.

Adjusted for maternal age, household size, schooling, health centre.

###### 

Results of whole genome sequencing of non-typable isolates.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Isolate N                                    CSS   Mother/infant   *S. pneumoniae* % reads   S*. pseudopneumoniae*\   ST           Nearest ST   Capsular locus top hit   Serotype specific sequence detected   Ancestral capsular type from phylogeny   Conclusion                                       VT or NVT
                                                                                               % reads                                                                                                                                                                                                     
  -------------------------------------------- ----- --------------- ------------------------- ------------------------ ------------ ------------ ------------------------ ------------------------------------- ---------------------------------------- ------------------------------------------------ -----------
  108887                                       1     Infant          78.08                     0.71                     3407                      16F                      16F                                   16F                                      16F not expressed                                NVT

  105098                                       1     Mother          80.51                     0.14                     1778                      34                       34                                    34                                       34 not expressed                                 NVT

  104550                                       1     Mother          19.47                     40.9                     Unknown                                                                                                                           *S. pseudopneumoniae*                            \-\--

  201376                                       2     Infant          80.46                     0.25                     5521                      10A                      10A                                   10A                                      10A not expressed                                NVT

  207381                                       2     Infant          82.09                     0.4                      Novel ST D   2052         20                       20                                    Long branch, inconclusive                20 not expressed                                 NVT

  206628                                       2     Infant          81.38                     0.08                     989                       12F                      12F/A/46                              12F/A/46                                 12F/A/46 not expressed                           NVT

  210240                                       2     Infant          80.96                     0.08                     989                       12F                      12F/A/46                              12F/A/46                                 12F/A 46 not expressed                           NVT

  210201                                       2     Infant          83.51                     0.08                     2447                      14                       14                                    14                                       14 not expressed                                 VT

  201867[a](#tblfn0035){ref-type="table-fn"}   2     Infant          46.64                     0.57                     Novel ST B   4040         Classical NT                                                   14                                       Capsule switch from 14 to classically NT locus   VT

  200954                                       2     Mother          81.22                     0.25                     Novel ST G   975          15B/C                    15B/C                                 15B/C                                    15B/C not expressed                              NVT

  206379                                       2     Infant          81.51                     0.16                     4033                      15B/C                    15B/C                                 15B/C                                    15B/C not expressed                              NVT

  207139                                       2     Infant          76.55                     0.57                     3407                      16F                      16F                                   16F                                      16F not expressed                                NVT

  210300                                       2     Infant          78.96                     0.62                     Novel ST F   3407         16F                      16F                                   16F                                      16F not expressed                                NVT

  210092                                       2     Infant          80.13                     0.28                     Novel ST E   847          19A                      19A                                   19A                                      19A not expressed                                VT

  210344                                       2     Infant          79.93                     0.19                     Unknown      7661         19B                                                            19B                                      19B not expressed                                NVT

  206438                                       2     Infant          81.8                      0.1                      202                       19A                      19A                                   Long branch, inconclusive                19A not expressed                                VT

  208478                                       2     Infant          81.95                     0.17                     4033                      19F                      19F                                   19F/15B/C                                19F not expressed                                VT

  202731                                       2     Infant          81.26                     0.08                     Novel ST C   6712         28A/F                                                          28A/F                                    28A/F not expressed                              NVT

  201297                                       2     Mother          81.95                     0.34                     5734                      6A/B/C/D                 6A/B/C/D                              6A                                       6A not expressed                                 VT

  201794                                       2     Infant          78.82                     0.8                      Novel ST A   71           38 (low match 35%)                                             Long branch, inconclusive                *cps* locus lost                                 \-\--

  201398                                       2     Mother          76.17                     1.3                      Novel ST H   3582         Classical NT                                                   Long branch, inconclusive                Capsule switch to classically NT locus           \-\--

  201843                                       2     Infant          77.28                     1.11                     4040                      Classical NT                                                   14                                       Capsule switch from 14 to classically NT locus   VT

  205597                                       2     Infant          75.37                     0.96                     Novel ST B   4040         Classical NT                                                   14                                       Capsule switch from 14 to classically NT locus   VT

  206158                                       2     Mother          78.28                     0.89                     Novel ST B   4040         Classical NT                                                   14                                       Capsule switch from 14 to classically NT locus   VT

  201133                                       2     Infant          64.27                     3.02                     344                       Classical NT                                                   Classical NT                             Classical NT                                     --

  202601                                       2     Mother          65.69                     2.64                     448                       Classical NT                                                   Classical NT                             Classical NT                                     --

  208136                                       2     Infant          66.12                     2.67                     448                       Classical NT                                                   Classical NT                             Classical NT                                     --

  201017                                       2     Infant          17.54                     43.18                    Unknown                                                                                                                           *S. pseudopneumoniae*                            --

  209574                                       2     Infant          20.05                     40.36                    Unknown                                                                                                                           *S. pseudopneumoniae*                            --
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CSS, cross-sectional; VT, vaccine-types; NVT, non-vaccine types; NT, non-typable; ST, sequence type.

Sample contaminated with unclassified organism, pneumococcal coverage sufficient for analysis and conclusions.
